Breaking News Instant updates and real-time market news.

CTIC

CTI BioPharma

$1.00

0.0188 (1.92%)

16:16
03/13/19
03/13
16:16
03/13/19
16:16

CTI BioPharma reports Q4 EPS 1c, consensus (28c)

Reports Q4 revenue $14.1M, consensus $250K.

  • 19

    Mar

CTIC CTI BioPharma
$1.00

0.0188 (1.92%)

03/26/18
NEED
03/26/18
INITIATION
Target $10
NEED
Buy
CTI BioPharma initiated with a Buy at Needham
Needham analyst Chad Messer initated CTI BioPharma with a Buy rating and a price target of $10, citing his view of pacritinib as an unusually de-risked asset based on the data from two Phase III studies and a "clear path to approval with the FDA". Messer adds that despite some recent recovery in the stock price, there is still "deep value" in CTI BioPharma shares. The analyst further notes the company's commercial presence with Pixuvri as a treatment in aggressive B-cell NHL which has a conditional approval in Europe.
03/26/18
03/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Altria Group (MO) initiated with a Buy at Deutsche Bank. 2. Sage Therapeutics (SAGE) assumed with a Buy at Canaccord. 3. Essa Pharma (EPIX) initiated with a Buy at H.C. Wainwright. 4. CTI BioPharma (CTIC) initiated with a Buy at Needham. 5. Saia (SAIA) initiated with a Buy at Buckingham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/10/18
JMPS
07/10/18
NO CHANGE
Target $8
JMPS
Outperform
CTI BioPharma only had modest pixantrone opportunity in EU, says JMP Securities
After CTI BioPharma announced that a Phase 3 study of pixantrone in B-cell non-Hodgkin lymphoma failed to meet its primary endpoint, JMP Securities analyst Konstantinos Aprilakis said that his projections for the drug in that indication in the EU were modest and removing it from his model did not change his $8 price target on the stock. Pacritinib and the "tremendous opportunity" for it in myelofibrosis have always been central to his investment thesis for CTI, added Aprilakis, who maintains an Outperform rating on the stock, which fell 14% to close at $4.48 on Monday.
03/05/19
LSCM
03/05/19
INITIATION
Target $4
LSCM
Buy
CTI BioPharma initiated with a Buy at Lake Street
Lake Street analyst Thomas Flaten started CTI BioPharma with a Buy rating and $4 price target. The company's targeted indication for pacritinib in myelofibrosis with severe thrombocytopenia represents an unmet clinical need and potential revenue opportunity of $450M, Flaten tells investors in a research note. Further, CTI's other compounds are not being developed for this niche indication, providing a "substantial pay-off" for the company should the clinical development of pacritinib bear fruit, says the analyst.

TODAY'S FREE FLY STORIES

NCMI

National CineMedia

$6.44

-0.03 (-0.46%)

07:11
06/19/19
06/19
07:11
06/19/19
07:11
Upgrade
National CineMedia rating change  »

National CineMedia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

MDB

MongoDB

$166.49

1.27 (0.77%)

07:11
06/19/19
06/19
07:11
06/19/19
07:11
Recommendations
MongoDB analyst commentary  »

MongoDB bulls likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

AXTA

Axalta Coating

$25.82

0.03 (0.12%)

07:10
06/19/19
06/19
07:10
06/19/19
07:10
Hot Stocks
Axalta Coating up 14% after announcing review of strategic alternatives »

In pre-market trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.80

1.21 (0.44%)

07:10
06/19/19
06/19
07:10
06/19/19
07:10
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:10
06/19/19
06/19
07:10
06/19/19
07:10
General news
FX Update: The dollar has seen moderate softness »

FX Update: The dollar has…

NBRV

Nabriva Therapeutics

$2.11

0.045 (2.18%)

07:09
06/19/19
06/19
07:09
06/19/19
07:09
Hot Stocks
Nabriva Therapeutics submits Type A Meeting Request to FDA for CONTEPO »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

ADBE

Adobe

$276.80

1.21 (0.44%)

07:09
06/19/19
06/19
07:09
06/19/19
07:09
Upgrade
Adobe rating change  »

Adobe upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$3.69

0.06 (1.65%)

07:08
06/19/19
06/19
07:08
06/19/19
07:08
Hot Stocks
Sorrento Therapeutics CEO to provide updates on CD38 immunotherapies »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTEC

Intec Pharma

$4.78

-0.02 (-0.42%)

07:07
06/19/19
06/19
07:07
06/19/19
07:07
Hot Stocks
Intec Pharma's Accordion Pill meets primary endpoint in PK study »

Intec Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$1.82

0.13 (7.69%)

07:07
06/19/19
06/19
07:07
06/19/19
07:07
Initiation
KemPharm initiated  »

KemPharm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCRB

Seres Therapeutics

$2.61

0.16 (6.53%)

07:06
06/19/19
06/19
07:06
06/19/19
07:06
Hot Stocks
Seres Therapeutics provides statement regarding FDA safety alert for FMT use »

Seres Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.80

1.21 (0.44%)

07:06
06/19/19
06/19
07:06
06/19/19
07:06
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$60.46

1.205 (2.03%)

07:04
06/19/19
06/19
07:04
06/19/19
07:04
Hot Stocks
Cubic announces sale of commercial properties in San Diego, Orlando for $46M »

Cubic announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYX

Systemax

$20.56

0.16 (0.78%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Conference/Events
Systemax management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 25

    Sep

PLXP

PLx Pharma

$4.93

-0.07 (-1.40%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Hot Stocks
PLx Pharma says 'on track' to file VAZALORE submission by year-end »

PLx Pharma announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDB

MongoDB

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Recommendations
MongoDB analyst commentary  »

MongoDB price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

SMLP

Summit Midstream

$6.90

0.13 (1.92%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Downgrade
Summit Midstream rating change  »

Summit Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PT

Pintec Technology

$4.38

-0.04 (-0.90%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Pintec Technology expands partnership with 1an.com »

Pintec Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:02
06/19/19
06/19
07:02
06/19/19
07:02
General news
MBA Mortgage Applications Composite Index data reported »

Week of 6/14 MBA Mortgage…

CTLT

Catalent

$50.48

-0.1 (-0.20%)

, BMY

Bristol-Myers

$47.79

-0.42 (-0.87%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Catalent tu purchase Bristol-Myers' manufacturing facility in Italy »

Catalent (CTLT) has…

CTLT

Catalent

$50.48

-0.1 (-0.20%)

BMY

Bristol-Myers

$47.79

-0.42 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 16

    Sep

AXTA

Axalta Coating

$25.82

0.03 (0.12%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Axalta Coating initiates review of strategic alternatives »

Axalta Coating announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$25.55

0.01 (0.04%)

07:01
06/19/19
06/19
07:01
06/19/19
07:01
Conference/Events
Regional Management management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 13

    Nov

ADBE

Adobe

$276.80

1.21 (0.44%)

06:58
06/19/19
06/19
06:58
06/19/19
06:58
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$84.30

2.21 (2.69%)

06:58
06/19/19
06/19
06:58
06/19/19
06:58
Recommendations
Nike analyst commentary  »

Nike survey shows weaker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

ADBE

Adobe

$276.80

1.21 (0.44%)

06:57
06/19/19
06/19
06:57
06/19/19
06:57
Recommendations
Adobe analyst commentary  »

Adobe growth to slow over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.